“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Wednesday, August 27, 2025

Alexion Pharmaceuticals


Alexion Pharmaceuticals — A to Z Product Catalog

  • Kanuma®
    • Generic: Sebelipase alfa (enzyme replacement therapy)
    • Indication: Lysosomal acid lipase deficiency (LAL-D)
    • Dose/Form: Intravenous infusion (20 mg/10 mL formulation)

  • Koselugo®
    • Generic: Selumetinib (MEK inhibitor)
    • Indication: Neurofibromatosis type 1–associated plexiform neurofibromas (PNF) in children
    • Dose/Form: Oral capsules (10 mg and 25 mg strengths)

  • Soliris®
    • Generic: Eculizumab (monoclonal antibody complement C5 inhibitor)
    • Indications: Paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), neuromyelitis optica spectrum disorder (NMOSD)
    • Dose/Form: Intravenous infusion

  • Strensiq®
    • Generic: Asfotase alfa (recombinant enzyme replacement)
    • Indication: Perinatal-, infantile-, and juvenile-onset hypophosphatasia
    • Dose/Form: Subcutaneous injection

  • Ultomiris®
    • Generic: Ravulizumab-cwvz (long-acting complement C5 inhibitor)
    • Indications: PNH, aHUS, generalized myasthenia gravis (gMG), NMOSD
    • Dose/Form: Intravenous infusion (weight-based maintenance dosing every 4–8 weeks)

  • Voydeya®
    • Generic: Danicopan (oral complement inhibitor)
    • Indication: Add-on therapy for extravascular hemolysis in PNH, used with Soliris or Ultomiris
    • Dose/Form: Oral tablets; typically 150 mg three times daily (up to 200 mg TID if needed)


    • on

    No comments:

    Post a Comment

    Subscribe to: Post Comments (Atom)